News | January 08, 2015

Guidance provides specific recommendations for amendments to make PMA approvable

EDAP TMS SA, Ablatherm, FDA, PMA, premarket approval, guidance
Image courtesy of EDAP TMS SA

January 8, 2015 — EDAP TMS SA received a letter from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) on its current premarket approval (PMA) application for the Ablatherm integrated imaging device for high-intensity focused ultrasound (HIFU). The FDA letter stated that while EDAP’s Ablatherm-HIFU PMA is not approvable in its current form, it provides specific guidance and recommendations as to a path forward. This guidance was provided in accordance with the requirements of 21 CFR 814.44(f), which states that the FDA, where practical, must identify measures necessary to make the PMA approvable.

Consistent with feedback received during the Gastroenterology and Urology Devices Panel meeting, the FDA has recommended considering a modified indication for use in a population of localized prostate cancer patients that have greater risk of morbidity and/or mortality from their disease. The FDA made further recommendations regarding the potential use of the company’s European registry, along with the already existing safety data from the previous U.S. investigational device exemption (IDE), to support approval for the modified indication. Although additional data and analyses will be necessary to address FDA’s requests, the letter did not require a new U.S. IDE study.

In order to continue the process, the company must submit a major amendment, to include the additional information requested by the FDA, by April 29, 2015. This major amendment, which will have the same PMA number as the company’s initial filing, may extend the FDA review period up to 180 days after submission.

HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment

For more information: www.edap-tms.com

Related Content

News | Focused Ultrasound Therapy

August 24, 2021 — Researchers are bringing the use of acoustic waves to target and destroy cancerous tumors closer to ...

Time August 24, 2021
arrow
News | RSNA

July 21, 2021 — Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly ...

Time July 21, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

July 13, 2021 — MRI-guided focused ultrasound combined with microbubbles can open the blood-brain barrier (BBB) and ...

Time July 13, 2021
arrow
News | Focused Ultrasound Therapy

July 1, 2021 — The University of Oxford announced commencement of enrollment for the Phase I PanDox study of ...

Time July 01, 2021
arrow
News | Focused Ultrasound Therapy

March 17, 2021 — On the heels of the country’s deadliest year for drug overdoses, the West Virginia University ...

Time March 17, 2021
arrow
News | Focused Ultrasound Therapy

March 2, 2021 — West Virginia University scientists used magnetic resonance imaging (MRI) scans to show what happens ...

Time March 02, 2021
arrow
News | Focused Ultrasound Therapy

February 16, 2021 — Insightec, a global healthcare company focused on creating the next generation of patient care ...

Time February 16, 2021
arrow
News | Focused Ultrasound Therapy

January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with Parkinson’s ...

Time January 08, 2021
arrow
News | Focused Ultrasound Therapy

December 18, 2020 — Philips and InSightec, a global healthcare company focused on the therapeutic power of acoustic ...

Time December 18, 2020
arrow
News | Focused Ultrasound Therapy

October 30, 2020 — A team of researchers in Madrid, Spain, and another team in Toronto, Canada, are the first in the ...

Time October 30, 2020
arrow
Subscribe Now